Insulet Q1 revenue $358.1M (+21% YoY); U.S. Omnipod revenue up 49%

First Quarter Financial Highlights: • First quarter 2023 revenue of $358.1 million, up 21.2%, or 23.3% in constant currency 1 , compared to $295.4 million in the prior year ◦ Total Omnipod revenue of $357.6 million, an increase of 32.7%, or 34.9% in constant currency ◦ U.S. Omnipod revenue of $259.0 million, an increase of 48.8% ◦ International Omnipod revenue of $98.6 million, an increase of 3.4%, or an increase of 9.6% in constant currency ◦ Drug Delivery revenue of $0.5 million, a decrease of 98.1% • Gross margin of 67.2%, down 380 basis points. Adjusted gross margin 1 of 64.9% excludes income of $8.0 million associated with the voluntary medical device correction (MDC) notices issued in 2022 • Operating income of $27.7 million, or 7.7% of revenue, compared to $37.9 million, or 12.8% of revenue, in the prior year. Adjusted operating income 1 of $19.7 million, or 5.5%, excludes income of $8.0 million noted above • Net income of $23.8 million, or $0.34 per diluted share, compared to $